Hormontherapie in der Peri- und Postmenopause und Malignomrisiko
Authors:
- 6 March 2013
- journal article
- leitthema
- Published by Springer Nature in Der Gynäkologe
- Vol. 46 (3) , 155-159
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior HysterectomyJAMA, 2011
- Reproductive History and Risk of Colorectal Cancer in Postmenopausal WomenJNCI: Journal of the National Cancer Institute, 2011
- Menopausal Hormone Therapy Does Not Influence Lung Cancer Risk: Results from the California Teachers StudyCancer Epidemiology, Biomarkers & Prevention, 2011
- Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone TherapyJNCI: Journal of the National Cancer Institute, 2011
- Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancerBreast Cancer Research and Treatment, 2010
- Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized TrialJNCI: Journal of the National Cancer Institute, 2010
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trialThe Lancet, 2009
- Conjugated Equine Estrogens and Colorectal Cancer Incidence and Survival: The Women's Health Initiative Randomized Clinical TrialCancer Epidemiology, Biomarkers & Prevention, 2008
- Conjugated Equine Estrogens and Breast Cancer Risk in the Women's Health Initiative Clinical Trial and Observational StudyAmerican Journal of Epidemiology, 2008
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002